All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

BeOne's Brukinsa (zanubrutinib) BTK inhibitor gains Scottish approval for relapsed mantle cell lymphoma after Ph2 trials
Small molecule, cancer, BTK inhibitor, mantle cell lymphoma, non-Hodgkin lymphoma, refractory disease - Read more

FDA approves Viatris' iron sucrose injection, first generic of Daiichi's Venofer for iron deficiency anemia
Small molecule, metabolic, iron therapy, anemia, chronic kidney disease, generic drug - Read more

THE GOOD
Business Development & Partnerships

Expedition Therapeutics, Fosun Pharma partner on lung disease drug, $17M upfront with potential $628M in milestones
Licensing deal, small molecule, respiratory disease, inflammatory disease, milestone payments, global - Read more

Sever Pharma, Silo Pharma expand partnership to develop ketamine implant for chronic pain treatment
Co-development, chronic pain, drug delivery, small molecule, manufacturing - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Novartis' ianalumab achieves Ph3 success targeting B cells in Sjögren's disease, positioning for first targeted therapy
Antibody, autoimmune, monoclonal antibody, Sjögren's syndrome, B-cell targeting, BAFF-R - Read more

THE GOOD
Fundraises

Longeveron raises $17.5M public offering for cell therapies targeting rare pediatric and aging conditions
Regenerative medicine, cell therapy, rare disease, clinical-stage, aging-related conditions, Alzheimer disease - Read more

Ligand raises $400M convertible notes offering for complementary business investments
Platform technology, pharmaceutical, drug discovery, small molecule - Read more

Ocugen raises $20M registered direct offering, gene therapies for blindness diseases
Gene therapy, ophthalmology, blindness diseases, clinical-stage - Read more

RBL venture creation studio secures undisclosed investment from Modi Ventures
Venture creation studio, biotech, platform technology, startup incubator, company formation - Read more

XORTX Therapeutics raises $114.5K private placement, advancing therapies for gout and kidney disease
Gout, kidney disease, clinical-stage, small molecule - Read more

THE GOOD
Mergers & Acquisitions

10x Genomics acquires Scale Biosciences to expand single cell analysis capabilities and increase research accessibility worldwide
Genomic technology, single cell analysis, strategic acquisition, major transaction - Read more

BridgeBio Oncology Therapeutics goes public via SPAC merger with Helix, now trading on Nasdaq as RAS-pathway cancer specialist
Small molecule, oncology, strategic, financial, major transaction - Read more

THE GOOD
Product Launches

Nxera Pharma launches oral GLP-1 and GPCR pipeline targeting obesity and metabolic diseases
Small molecule GLP-1 agonist, metabolic disease, obesity, strategic, pipeline expansion - Read more

ProBio launches GMP AAV manufacturing at Hopewell facility, offering end-to-end gene therapy production services
Gene therapy manufacturing, AAV vector production, operational, strategic expansion, CDMO - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

IO Biotech's melanoma vaccine Cylembio narrowly misses Ph3 primary endpoint but shows promise in PD-L1/IDO1 targeting
Vaccine, cancer, cancer vaccine, melanoma, immunotherapy, combination therapy - Read more

THE BAD
Company Shutdown

NextRNA Therapeutics winds down after missing milestone in $547M oncology deal
Oncology, small molecule, licensing deal, milestone payments, research collaboration - Read more

THE BAD
Layoffs

Cold Chain Technologies to cut 82 jobs in Massachusetts, shifting operations to Texas and Tennessee
Cold chain logistics, operational, cost reduction, strategic relocation - Read more

THE UGLY
Politics & Policy

MAHA leader Gray Delany fired after clashing with HHS officials over RFK Jr.'s $500M mRNA contract terminations
mRNA vaccine, infectious disease, regulatory, strategic, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here